BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Sellas Life Sciences Group readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of studies Sellas Life Sciences Group's drug
 s run\, from ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT04588922-3077@assetmemo.bio
DTSTAMP:20261121T005636Z
DTSTART;VALUE=DATE:20261230
DTEND;VALUE=DATE:20261231
SUMMARY:Tambiciclib: Phase 1/2 readout est. (NCT04588922)
DESCRIPTION:Tambiciclib\, phase 1/2\, Acute Myeloid Leukemia.\nStudy: Study
  of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in P
 atients With Hematologic Malignancies and High-Risk Newly Diagnosed AML\nE
 stimated primary completion: 30 December 2026. This is a ClinicalTrials.go
 v estimate\, not a confirmed readout date\, and it can move.\nDrug page: h
 ttps://assetmemo.bio/drug/tambiciclib#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT04588922
URL:https://assetmemo.bio/drug/tambiciclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
